Q4 2019 Marrone Bio Innovations Inc Earnings Call

By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations (NASDAQ:MBII) reported record revenue and a further increase in gross margins in the first quarter of 2020. Costs were impacted by the addition of Pro Farm which did not make a significant impact on revenue. Both Regalia and Venerate were strong contributors during the quarter. COVID-19 did not have a

Marrone Bio Innovations, Inc. (MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, announced today that REGALIA® MAXX biofungicide received the first approval for indoor and outdoor use on cannabis and hemp in Canada. Cannabis and hemp have been relatively small crops in Canada until lifestyle cannabis was approved in 2018. According to Health Canada, 77,800 acres of hemp were grown in 2018, valued at an estimated $50 million USD.

DAVIS, Calif., April 14, 2020 -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, today announced.

By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations' (NASDAQ:MBII) new plant health product, Pacesetter, received EPA approval in February, 2020 and state approval in the major corn, soybean and wheat states is expected before the growing season. Fungicide application months are usually Jun/July for Corn; May/June for Soybean and May/June for wheat.

Marrone Bio Innovations Inc. (MBII), an international leader in sustainable bioprotection and plant health solutions, today announced that Pacesetter™, a recently approved bio-based plant health product, is now available to corn, soybean and wheat growers in the United States. Pacesetter acts synergistically with conventional fungicides to improve plant health and vigor, increasing yield by up to seven bushels per acre in soybeans and 13 bushels per acre in corn.

Q1 2020 Marrone Bio Innovations Inc Earnings Call

DAVIS, Calif., May 26, 2020 -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today.

Marrone Bio Innovations, Inc. (MBII) (the “Company”) today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) as a result of the company’s closing bid price being below $1.00 per share for 30 consecutive days. Under Nasdaq Listing Rules, the Company usually has 180 calendar days from the date of the notification to regain compliance with Nasdaq Listing Rules.

Local companies and business leaders are doing what they can to help the community during the COVID-19 outbreak.

Marrone Bio Innovations Inc. (MBII) (the “Company” or “Marrone Bio”), an international leader in sustainable bioprotection and plant health solutions, today provided a corporate update on recent corporate governance and operational initiatives. In December 2019, Marrone Bio’s Board of Directors announced that the Company’s founder, Dr. Pamela Marrone, would retire from her position as chief executive officer. At that time, the Board of Directors initiated a search process for a new CEO, and subsequently have identified a final candidate for consideration.

Davis-based Marrone Bio Innovations Inc. received $1.7 million in funding under the Paycheck Protection Program, the federal government's main initiative to help small businesses disrupted by the COVID-19 pandemic.

By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations (NASDAQ:MBII) has announced that it has received the first approval of the use of REGALIA MAXX biofungicide for the use on cannabis and hemp (hemp and marijuana are two varieties of the same plant cannabis sativa) in Canada. Cannabis is susceptible to powdery mildew. It can destroy complete crops and

DAVIS, Calif., May 01, 2020 -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, will release.

Pam Marrone became the CEO of Marrone Bio Innovations, Inc. (NASDAQ:MBII) in 2006. First, this article will compare...

Marrone Bio Innovations, Inc. (Nasdaq: MBII) (MBI),  a leading provider of effective and environmentally responsible pest management and plant health products, announced today that its Form S-1 resale registration statement relating to the potential resale of shares of common stock, including common stock issuable upon the exercise of warrants, held by certain shareholders of the Company has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) on March 30, 2020. "This registration statement was filed to comply with the terms of our private placement and debt refinancing transactions that we completed in February 2018, as well as the warrant financing transactions we previously announced in August 2019," said Jim Boyd, the Company's Chief Financial Officer.

Marrone Bio Innovations Inc. (MBII) (the “Company” or “Marrone Bio”), an international leader in sustainable bioprotection and plant health solutions, has secured a $1.7 million loan under the Paycheck Protection Program (PPP) (the “Loan”) contained within the Coronavirus Aid, Relief and Economic Security (CARES) Act that was signed into law on March 27, 2020. As a U.S. small business, Marrone Bio qualified for the PPP, which allows businesses and nonprofits with fewer than 500 employees to obtain loans of up to $10 million to incent companies to maintain their workers as they manage the business disruptions caused by the COVID-19 pandemic.

Record Revenues; Seventh Consecutive Quarter of Year Over Year Revenue Growth Realized in Challenging Environment for Agricultural Production Record Gross Margins Mark Sixth.

By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Following the recent Form S-1 registration of stock and warrants (outlined below), the major stockholders and Marrone Bio Innovations (NASDAQ:MBII) have signed a warrant exchange agreement. Under the agreement 46 million existing warrants will be swapped for 29.9 million new warrants with various expiration dates and an

Marrone Bio Innovations, Inc. (MBII) (the “Company” or “Marrone Bio”) an international leader in sustainable bioprotection and plant health solutions, has signed a warrant exchange agreement with existing institutional investors that immediately reduces the total number of outstanding warrants by approximately 35%, from 52.6 million to 36.5 million. The warrant exchange transaction was entered into between the Company and existing investors Waddell & Reed, Ospraie Ag Science LLC, Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation and Ivan Saval.